相关实验视频

Updated: Jul 15, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

与新辅助疗法相关的免疫反应在食道状细胞癌的瘤微环境中

Yuka Takehara¹, Tomoaki Tamaki¹, Kosaku Mimura^2,3

¹Department of Radiation Oncology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Anticancer research

|September 29, 2023

概括

新辅助化学疗法 (NAC) 和化学放射疗法 (NACRT) 通过增加CD8+ T细胞和HLA I类表达,增强食道状细胞癌 (ESCC) 的抗瘤免疫力. 这些发现支持用于高级ESCC的联合免疫疗法.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

包括免疫检查点抑制剂在内的多学科疗法对于食道状细胞癌 (ESCC) 是至关重要的.
了解化疗后瘤微环境中的免疫反应,有或没有放射治疗,对于开发有效的治疗方法至关重要.

研究的目的:

研究新辅助化疗 (NAC) 和新辅助化疗或放射治疗 (NACRT) 后食道状细胞癌 (ESCC) 患者瘤微环境中的免疫变化.
在新辅助治疗后,评估关键免疫标记物的表达,包括CD8,HLA类I,PD-L1和相关的信号分子.

主要方法:

从49名经过手术的ESCC患者的结对瘤样本的回顾性分析.
患者接受了NAC (n=30),NACRT (n=11) 或单独进行手术 (n=8).
免疫组织化学被用来评估CD8,HLA类I-ABC,PD-L1,PD-L2,CEACAM-1和p-STAT1.1的表达.

主要成果:

NAC显著增加了瘤透CD8+T细胞的频率.
无论是NAC还是NACRT,都显著增加了瘤细胞上HLA类I-ABC的表达.
ESCC细胞表达PD-L1,PD-L2和CEACAM-1,PD-L1的表达与瘤细胞中的p-STAT1相关.

结论:

新辅助化疗和化疗辐射疗法在ESCC中诱导了有益和有害的免疫反应.
这些发现为将免疫检查点抑制剂纳入高级ESCC的多学科治疗策略提供了基础.

关键词:

CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD9 CD8 CD8 CD8 CD9 CD8 CD9 CD8 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 是一个字体的字体的字体是什么意思食道癌是食道癌的一个类型.HLA 一级的I类.作为一种新辅助疗法,

更多相关视频

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...